Iuliana Shapira, MD, chief medical officer, Regional Cancer Care Associates (RCCA), discusses how data analytics have improved RCCA’s revenue cycle.
Iuliana Shapira, MD, chief medical officer, Regional Cancer Care Associates (RCCA), discusses how data analytics have improved RCCA's revenue cycle.
Transcript
How as data analytics improved your revenue cycle?
Data analytics is a fabulous tool because by collecting data, we know at what point in the revenues cycles we have the problems. So, we know if problems are at various stages and how to address those barriers. Is data analytics ready for prime time? It depends what data comes in. A way to scrub and curate the data as it relates to revenue cycle is needed. A lot of the problems we have in revenue cycle nowadays are handled by highly specialized individuals who have training in billing, coding, insurance verification, benefits verification, and other areas of the revenue cycle.
However, it would be fantastic if we could address with artificial intelligence and big data certain aspects of the revenue cycle, such as insurance verification. We collect insurance information at the first patient visits, but if in between the visits, in the time interval the patient changes insurance, we do now have a mechanism right now to capture that, and I don’t think that artificial intelligence is ready to capture that right now. However, I know there are many software products and many companies that are working diligently to improve that situation.
Sequencing CAR T and Bispecifics for Multiple Myeloma: Tyler Sandahl, PharmD
July 8th 2025Tyler Sandahl, PharmD, a clinical pharmacist at Mayo Clinic, explains that sequencing novel multiple myeloma therapies with CAR T-cell therapy is generally prioritized first for eligible patients, while bispecific antibodies are reserved for later lines or for patients unable to tolerate CAR T.
Read More
Targeting the Root of gMG With Inebilizumab: A Q&A With Richard Nowak, MD, MS
June 24th 2025In this interview, Richard J. Nowak, MD, MS, principal investigator of the MINT trial of inebilizumab for generalized myasthenia gravis (gMG), discusses the trial’s key findings, including significant improvements in patient- and physician-assessed outcomes, as well as longer-term implications and future areas of investigation.
Read More
Accessibility Important After FDA Approves Lenacapavir for PrEP: Q&A With Colleen Kelley, MD, MPH
June 20th 2025The approval of lenacapavir, a form of pre-exposure prophylaxis (PrEP), marks significant progress in preventing HIV, making it vital for the treatment to be available and accessible to those most vulnerable, explains Colleen Kelley, MD, MPH, Rollins School of Public Health at Emory University.
Read More